These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 11794352)

  • 1. The prescription drug marketing act: a solution in search of a problem?
    Angarola RT; Beach JE
    Food Drug Law J; 1996; 51(1):21-55. PubMed ID: 11794352
    [No Abstract]   [Full Text] [Related]  

  • 2. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date; reopening of administrative record. Food and Drug Administration, HHS. Final rule; delay of effective date; reopening of administrative record.
    Fed Regist; 2000 May; 65(86):25639-41. PubMed ID: 11010689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 1999 Dec; 64(232):67720-63. PubMed ID: 11010665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prescription Drug Marketing Act of 1987.
    Greenberg RB
    Am J Hosp Pharm; 1988 Oct; 45(10):2118-26. PubMed ID: 3228083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new drug marketing: a consumer protection perspective.
    Woodward D
    Food Drug Law J; 1996; 51(4):637-50. PubMed ID: 11797733
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug marketing exclusivity under United States and European Union law.
    Junod V
    Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
    [No Abstract]   [Full Text] [Related]  

  • 7. Not as easy as it may appear: using radio frequency identification technology to fulfill the Prescription Drug Marketing Act's elusive pedigree requirement.
    Asamoah AK
    Food Drug Law J; 2006; 61(2):385-418. PubMed ID: 16903035
    [No Abstract]   [Full Text] [Related]  

  • 8. Prescription Drug Marketing Act Pedigree Requirements; effective date and compliance policy guide; request for comment. Final rule; announcement of effective date; notice of availability; request for comment.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jun; 71(114):34249-51. PubMed ID: 16795943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supreme Court decision may have major impact on drug industry.
    Spurgeon D
    CMAJ; 1993 Feb; 148(4):629-31. PubMed ID: 8431828
    [No Abstract]   [Full Text] [Related]  

  • 10. Unlabeled drug samples and the learned intermediary: the case for drug company liability without preemption.
    Poser S
    Food Drug Law J; 2007; 62(4):653-94. PubMed ID: 18557225
    [No Abstract]   [Full Text] [Related]  

  • 11. Distribution of certain drug products by registered blood establishments and comprehensive hemophilia diagnostic treatment centers that qualify as health care entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements and administrative procedures. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Oct; 73(197):59496-501. PubMed ID: 18985968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FDA Export Reform and Enhancement Act of 1996: the FDA's new extraterritorial authority over labeling and promotional practices.
    Helmanis AM
    Food Drug Law J; 1996; 51(4):631-5. PubMed ID: 11797732
    [No Abstract]   [Full Text] [Related]  

  • 13. The final sampling regulations of the Prescription Drug Marketing Act are alive and well: is your sampling program compliant?
    Romanski JA
    Food Drug Law J; 2003; 58(4):649-60. PubMed ID: 15027455
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmaceutical industry restructuring and new marketing approaches: enforcement responses.
    Mahinka SP; Sanzo KM
    Food Drug Law J; 1995; 50(2):313-25. PubMed ID: 10343000
    [No Abstract]   [Full Text] [Related]  

  • 15. GATT implementation and generic drug approval.
    Safir PO; Lassman SM
    Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203
    [No Abstract]   [Full Text] [Related]  

  • 16. Legalized importation of Canadian prescription drugs: short-term solution to a long-term problem.
    Teufel AT
    J Contemp Health Law Policy; 2006; 22(2):383-408. PubMed ID: 17117702
    [No Abstract]   [Full Text] [Related]  

  • 17. A patient's right of privacy in computerized pharmacy records.
    Mowery G
    Univ Cincinnati Law Rev; 1998; 66(2):697-746. PubMed ID: 16211743
    [No Abstract]   [Full Text] [Related]  

  • 18. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 19. Pediatric marketing exclusivity--as altered by the Best Pharmaceuticals for Children Act of 2002.
    Cooper KJ
    Food Drug Law J; 2002; 57(3):519-44. PubMed ID: 12710409
    [No Abstract]   [Full Text] [Related]  

  • 20. Compliance policy guide addresses prescription drug compounding.
    Ann Pharmacother; 1992 Jun; 26(6):868. PubMed ID: 1611176
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.